Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,551.81
(
-0.83%
)
US TECH 100
23,430.80
(
-1.22%
)
Dow Jones
45,868.52
(
-0.33%
)
Brent Oil
107.12
(
2.57%
)
Bitcoin
69,772.67
(
-0.18%
)
News Focus
News Focus
Post# of 257262
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122802
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: jq1234 post# 166749

Friday, 09/20/2013 11:58:03 AM

Friday, September 20, 2013 11:58:03 AM

Post# of 257262
ABBV/ENTA will present the six global registrational trials as a group, which means none of these trials will be presented at 2013 AASLD. (AASLD will, however, have some phase-2 data on the 2-DAA regimen of ABT-450 + ABT-267.)

Top-line data from some of the registrational phase-3 trials will likely be announced via PR, but the companies have not yet made any commitment with respect to timing.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today